Established safety and tolerability at 52 weeks with GEMTESA1,2

Patient having a conversation. GEMTESA® has an established safety and tolerability profile at 52 weeks.

Adverse reactions reported in 2% of patients treated with
GEMTESA 75 mg for up to 52 weeks1,2

  GEMTESA
n (%)
NUMBER OF PATIENTS 273
URINARY TRACT INFECTION 18 (6.6%)
BRONCHITIS 8 (2.9%)

Adverse reactions reported in 2% of patients treated with GEMTESA 75 mg for up to 52 weeks in the long-term extension study, and not already listed in the 12-week adverse events table, were urinary tract infection and bronchitis.1

Take a look at the 52-week data for
GEMTESA

Extension study
Doctor prepared to discuss GEMTESA and OAB with patients.
 

References: 1. GEMTESA Prescribing information. Urovant Sciences GmbH; 2020. Accessed January 4, 2021. https://gemtesa.com/sites/default/files/gemtesa-prescribing-information.pdf 2. Data on file, Urovant Sciences GmbH.